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Graphical Abstract
Urolithin A is a gut-derived metabolite of fruits such as pomegranate. In this study we 
investigated molecular mechanisms involved in the neuroprotective actions of this 
compound. The outcome of the experiments showed that urolithin A produced 
inhibition of neuroinflammation and amyloid beta neurotoxicity by activating DNA 
deacetylation mechanisms and induction of autophagy in BV2 microglia and human 
neural progenitor cells.
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Abstract
1. Scope
Urolithin A is an anti-inflammatory and neuroprotective gut-derived metabolite from 
ellagitannins and ellagic acid in pomegranate, berries and nuts. We investigated the 
roles of SIRT-1 and autophagy in the neuroprotective activity of urolithin A. 
2. Methods and results
Analyses of culture supernatants from lipopolysaccharide-stimulated BV2 microglia 
showed that urolithin A (2.5-10 µM) produced significant reduction in the production 
of nitrite, tumour necrosis factor (TNF) α and interleukin (IL)-6. Anti-inflammatory 
effect of the compound was reversed in the presence of sirtuin (SIRT)-1 and the 
autophagy inhibitors EX527 and chloroquine, respectively. Protein analyses revealed 
reduction in p65 and acetyl-p65 protein. Treatment of BV2 microglia with urolithin A 
resulted in increased SIRT-1 activity and nuclear protein, while induction of 
autophagy by the compound was demonstrated using autophagy fluorescent and 
autophagy LC3 HiBiT reporter assays. Viability assays revealed that urolithin A 
produced neuroprotective effect in APPSwe-transfected ReNcell VM human neural 
cells, which was reversed in the presence of EX527 and chloroquine. Increase in 
both SIRT-1 and autophagic activities were also detected in these cells following 
treatment with urolithin A.
3. Conclusions
We propose that SIRT-1 activation and induction of autophagy are involved in the 
neuroprotective activity of urolithin A in brain cells.
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1. Introduction
Neuroinflammation is progressively becoming a critical process in many 
neurodegenerative diseases including Alzheimer’s (AD) and Parkinson’s diseases 
(PD). Neuroinflammation is activated by mechanisms such as oxidative stress and 
activation of brain resident macrophages known as microglia1. Furthermore, 
mediators, such as pro-inflammatory cytokines, released during neuroinflammation 
are critical in neurodegeneration1.
Sirtuin-1 (SIRT-1), an NAD+-dependent class III histone deacetylase, is known to 
play a significant role in suppressing the release of pro-inflammatory cytokines2,3. In 
microglia, over-expression of SIRT-1 has been demonstrated to inhibit microglia 
activation4. Furthermore, the SIRT-1 activator resveratrol has been reported to 
inhibit neuroinflammation in LPS-activated rat primary microglia5 and in cultured 
astrocytes6. These observations were further confirmed by recent findings which 
have shown that SIRT-1 activation is neuroprotective against neuronal apoptosis, 
neuroinflammation and oxidative stress7. Autophagy is a catabolic process that is 
critical in the degradation of cytoplasmic proteins in multicellular organisms. Several 
lines of evidence have linked autophagy to neuroinflammation8 as well as to 
neurodegeneration9. Consequently, pharmacological modulation of brain SIRT-1 
and autophagy with nutritional factors is a promising strategy in neurodegenerative 
diseases.
Urolithins are bioavailable metabolites that are produced by the human gut 
microbiota from ellagitannins and ellagic acid found in food products such as 
pomegranate, berries, and nuts. Several biological activities have been reported for 
the urolithins; they were reported to inhibit inflammation in vivo in rat model of 
inflammatory bowel disease10, as well as in vitro in human colonic fibroblasts11, 
RAW 264.7 murine macrophages12, 13 and BV2 microglia14. Studies by DaSilva et 
al. have also shown that urolithins inhibited neuroinflammation in LPS-stimulated 
BV2 microglia and protected SH-SY5Y cells from oxidative stress-induced toxicity15. 
Furthermore, urolithin A was shown to extend the lifespan of C. elegans and 
improves muscle function in mice through upregulation of mitophagy16. In this study, 
we aimed to establish the roles of SIRT-1-mediated deacetylation and autophagic 
flux in the neuroprotective activity of urolithin A, the most active urolithin.
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2. Materials and methods
2.1Cell culture and treatments
The BV2 mouse microglia cell line (ICLC ATL03001; Interlab Cell Line Collection, 
Banca Biologica e Cell Factory, Italy) was cultured in RPMI1640 medium with 10% 
fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin 
and 100 mg/ml streptomycin in a 5% CO2 incubator. 
HEK293 (ECACC 85120602) cells were obtained from the European Collection of 
Cell Cultures (ECCAC) (Salisbury, UK) and were cultured in MEM-eagle’s medium 
(Thermo Scientific). MEM medium was supplemented with 10% FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, 2 mM L- glutamine, 100 U/ml penicillin, and 100 
mg/ml streptomycin in a 5% CO2 incubator.
Immortalised neural progenitor cells (ReNcell VM cells) were acquired commercially 
from Millipore (Hertfordshire, UK) and maintained as earlier described17. Cells were 
differentiated by replacing the culture medium with ReNcell NSC maintenance 
medium without the growth factors EGF and FGF-2 for 14 days. Differentiation into 
neurons was confirmed by immunocytochemical staining for βIII-tubulin and MAP217 
(Supplementary Figure S1-S3).
Urolithin A (Santa Cruz), EX527 (Sigma) and chloroquine (Arcos Organics) were 
prepared in dimethylsulfoxide (DMSO) for pharmacological experiments. The 
percentage of DMSO in cell culture was 0.2%. For all experiments, 5 x 104 cells/ml 
were seeded out in culture plates.
2.2Dosage information
Treatment of these cells with urolithin A (2.5-10 µM) with LPS stimulation for 24 h did 
not affect cell viability (Supplementary Figure S4).
2.3Determination of pro-inflammatory mediator release
BV2 microglia were pre-treated with urolithin A (2.5-10 µM) or vehicle (0.2% DMSO). 
After 30 min, cells were stimulated with LPS (100 ng/ml) for 24 h. Levels of nitrite in 
culture medium were determined using the Griess reagent (Promega), according to 
the manufacturer’s instructions. Production of TNFα and IL-6 was determined using 
mouse ELISA kits (Biolegend), according to the manufacturer’s instructions. 
Detection limits were 1.5 pg/ml and 2 pg/ml for TNFα and IL-6, respectively. These 
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experiments were also carried out in cells treated with SIRT-1 inhibitor 
(EX527; 1 µM) or autophagy inhibitor (chloroquine; 40 µM) 30 min before addition of 
urolithin A (10 µM) and stimulation with LPS (100 ng/ml).
2.4Transfection of ReNcell VM human neural stem cells with APPSwe 
plasmids 
Differentiated ReNcell VM cells were transfected with APPSwe plasmids as 
described and reported earlier17. Transfected cells were treated with urolithin A 
(2.5-10 µM) for 48 h. Cell viability was evaluated using MTT and LDH viability 
assays. Levels of Aβ42 in culture medium of cells treated with urolithin A for 14 days 
were determined by using a human Aβ42 ELISA kit (Life Technologies). Cell viability 
experiments were also carried out in cells treated with SIRT-1 inhibitor 
(EX527; 1 µM) or autophagy inhibitor (chloroquine; 40 µM) 30 min prior to treatment 
with urolithin A (10 µM).
2.5Immunofluorescence microscopy
Immunofluorescence detection for NF-Bp65, acetyl-p65, SIRT-1, nestin, βIII-tubulin, 
and MAP2 proteins was carried with Alexa Fluor 488-conjugated donkey anti rabbit 
IgG secondary antibody (Life Technologies; 1:500) and images were obtained using 
EVOS® FLoid® cell imaging station as described elsewhere15, 16.
2.6In-cell western for quantitative immunocytochemistry measurement of 
protein levels
This is a rapid method for quantification of proteins in cells. The method is similar to 
immunoblotting and immunocytochemistry and combines the specificity achieved 
with immunoblotting with the quantification capability of ELISA. BV2 microglia were 
seeded into a 96-well plate at a density of 5 x 104 cells/ml. Thereafter, cells were 
treated with urolithin A (2.5-10 M), and then stimulated with LPS (100 ng/ml) for 
60 min. Cell fixation was achieved with 8% paraformaldehyde solution, followed by 
overnight incubation with primary antibodies. The following antibodies were used: 
phospho-p65 NF-B (1:200; Cell Signalling), acetyl-p65 NF-B (1:200; Cell 
Signalling). This was followed by incubation with anti-rabbit HRP secondary antibody 
for 2 h at room temperature. Then, 100 µL HRP substrate was added to the plate 
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and signal measured at 450nm with a microplate reader. Readings were normalised 
with Janus Green stain (Abcam).
2.7SIRT-1 ELISA and activity assay
Cultured BV2 microglia or differentiated ReNcell VM human neural cells were treated 
with urolithin A (2.5-10 µM) for 24 h. Thereafter, nuclear extracts were collected for 
analysis of SIRT-1 using either mouse or human SIRT-1 ELISA kit (Abcam), 
according to the manufacturer’s instructions. SIRT-1 activity in cultured cells was 
also evaluated using the luminescent SIRT-Glo™ Assay (Promega), according to the 
manufacturer’s instructions and described earlier18, 19.
2.8Autophagy fluorescent assay
This experiment was carried out using an autophagy assay kit (Sigma), which 
provides a simple and direct approach for detecting autophagy in cells by employing 
a fluorescent autophagosome marker. BV2 or differentiated ReNcell VM cells were 
treated with urolithin A (2.5-10 µM) for 24 h. Thereafter, medium was removed and 
the cells were incubated with autophagosome detection reagent at 37°C with 5% 
CO2 for 1 h. Fluorescence intensity (ex = 360/em = 520 nm) was measured using a 
Polarstar Optima Plate microplate reader.
2.9Autophagy LC3 HiBiT reporter assay
The autophagy LC3 HiBiT reporter vector (Promega) has a HiBiT tag and contains a 
sequence encoding the MAP1LC3B gene. On induction of autophagy, LC3 reporter 
proteins are trapped in autophagosomes and degraded. HEK293, BV2 microglia, or 
differentiated ReNcell VM cells were transfected with the autophagy LC3 HiBiT 
reporter vector using Fugene 6 transfection reagent (Promega) and incubated for 
16 h at 37ºC in 5% CO2. Thereafter, transfected cells were plated in white 96-well 
plates and treated with urolithin A (2.5-10 µM) for 6 h. Then, 100 μl of Nano-Glo® 
HiBiT lytic reagent (Promega) was added to each well and the samples were mixed 
using an orbital shaker for 2 min. Luminiscence was measured on a Polarstar 
Optima Plate microplate reader.
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2.10 Statistical analysis
Values of all experiments were represented as a mean ± SEM of at least 3 
experiments. Values were compared using one-way ANOVA followed by a post hoc 
Tukey test.
3. Results and discussion
3.1Urolithin A inhibits neuroinflammation and acetylation of NF-B in 
LPS-activated BV2 microglia
Firstly, we were interested in establishing an anti-inflammatory activity for urolithin A 
in LPS-activated BV2 microglia. Our results showed that treatment with LPS 
(100 ng/ml) resulted in a significant (p<0.001) elevation in the levels of TNFα, IL-6, 
and nitrite in cell culture supernatants (Figure 3A). However, pre-treatment with 
urolithin A (2.5-10 µM) resulted in a significant (p<0.01) and concentration-
dependent reduction in the release of TNFα and nitrite. Levels of IL-6 was also 
decreased significantly and but not in a concentration-dependent manner. Inhibition 
of neuroinflammation by the compound was further confirmed using quantitative in 
cell ELISA and immunofluorescence experiments showing inhibition of LPS-induced 
phosphorylation (Figure 2B) nuclear accumulation (Supplementary Figure S5A) of 
NF-B in BV2 cells. Similar anti-inflammatory effects have been reported for urolithin 
A and other urolithins in BV2 microglia14, 15. 
It has been suggested that phase II glucuronide and sulfate conjugate metabolites of 
urolithins may be more physiologically relevant than the urolithins in order to produce 
pharmacological actions in vivo 20. However, in addition to demonstrating in vivo 
neuroprotective activity of urolithins, Yuan et al used in silico computational studies 
to predict blood-brain barrier permeability of the compounds 21). The relative in vivo 
neuroprotective activities of urolithins and their phase II metabolites therefore 
warrant further investigation.
In neuroinflammation, activation of NF-B and subsequent transcriptional regulation 
of pro-inflammatory genes involves post-translational modifications such as 
reversible acetylation of the NF-κB-p65 subunit22. Our investigations demonstrated 
that treatment with urolithin A reduced protein levels of acetyl-p65 in BV2 microglia 
stimulated with LPS (Figure 2C and Supplementary Figure S5B). We report here for 
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the first time that inhibition of LPS-induced acetylation of p65 by urolithin A is a 
critical mechanism in the anti-inflammatory activity of the compound, thus suggesting 
a role for nuclear histone deacetylation mechanisms.
3.2The role of SIRT-1 activation in the inhibition of neuroinflammation by 
urolithin A in BV2 microglia
Sirtuins (SIRTs) are class III histone deacetylases (HDACs), and have been strongly 
linked to regulation of neuroinflammation and neurodegeneration23, 24. Specifically, 
SIRT-1 activation prevents NF-B activation through mechanisms involving 
deacetylation of the p65 subunit25. Furthermore, inhibition of SIRT-1 in 
LPS-activated microglia has been observed to correlate with increased production of 
inflammatory cytokines26, 27.
Encouraged by our results showing that urolithin A reduced protein levels of 
acetyl-p65 in LPS-stimulated microglia, we were interested in evaluating whether this 
compound produces a direct activation of SIRT-1 in BV2 microglia. ELISA 
experiments showed that at 2.5 µM of urolithin A, the increase in nuclear SIRT-1 
protein was not significant when compared with untreated cells (Figure 3A). 
However, nuclear SIRT-1 protein levels in cells treated with 5 and 10 µM of the 
compound were significantly (p<0.05) higher than the levels in untreated cells. 
Similarly, significant (p<0.01) SIRT-1 activity was observed in BV2 cells treated with 
5 and 10 µM of urolithin A (Figure 3B). These results were further confirmed by 
immunofluorescence microscopy for the detection of SIRT-1 in BV2 cells 
(Supplementary Figure S6).
Experiments were thereafter carried out to confirm a direct involvement of SIRT-1 in 
the anti-inflammatory activity of urolithin A in LPS-activated microglia. In this case, 
BV2 cells were treated with EX527 (1 µM) prior to urolithin A (10 µM) followed by 
LPS stimulation for 24 h. Analyses of cell culture supernatants revealed that urolithin 
A treatment significantly (p<0.05) diminished LPS-induced release of TNFα, IL-6, 
and nitrite (Figure 4). However, in the presence of EX527, the anti-inflammatory 
activity observed by urolithin A treatment was reversed (Figure 4). A similar outcome 
is depicted in Supplementary Figure S7, showing a partial reversal in the inhibition of 
LPS-induced nuclear accumulation of NF-B p65 sub-unit in BV2 microglia in the 
presence of EX527.
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Taken together, these results show for the first time that urolithin A produces a direct 
activation of SIRT-1 in BV2 microglia. The outcome of these experiments also 
suggests that SIRT-1 is required for the anti-inflammatory activity of urolithin A in 
BV2 microglia. These are interesting observations as neuroprotective dietary 
compounds in fruits and vegetables such as kaempferol, quercetin, acacetin, 
apigenin, rutin and luteolin have been previously shown to produce NF-B-mediated 
inhibition of neuroinflammation and to provide health benefits through the activation 
of SIRT-128. Recently, we showed that compounds such as thymoquinone and 
agathisflavone produced inhibition of neuroinflammation in LPS-activated BV2 
microglia through mechanisms involving SIRT-118, 19. There have also been reports 
linking SIRT-1 activation to anti-inflammatory and neuroprotective actions of 
resveratrol29 further confirms our results. SIRT-1-mediated inhibition of 
neuroinflammation by dietary phytochemicals and their metabolites is a remarkable 
development with significant implications in nutritional strategies for 
neuroinflammation-mediated neurodegeneration in the ageing brain.
3.3Induction of autophagic flux contributes to inhibition of neuroinflammation 
by urolithin A
Recent reports have suggested that urolithin A increases autophagy13, 16. We were 
therefore interested in evaluating whether this compound induces autophagy in BV2 
microglia, and whether increasing autophagic flux contributes to its anti-inflammatory 
activity in LPS-activated BV2 microglia. To answer the first question, we investigated 
the effect of urolithin A treatment in an autophagy fluorescent assay, which is assay 
is based on the fluorescent activity of an autophagosome marker. Results in 
Figure 5A show that treatment with urolithin A (5 and 10 µM) resulted in a significant 
(p<0.05) increase in autophagic activity, when compared to untreated cells. 
Next, we transfected both HEK293 and BV2 cells with the autophagy LC3 HiBiT 
reporter vector followed by urolithin A treatment. This approach was used due to low 
transfection efficiency normally observed in BV2 microglia. Results obtained from 
easy-to-transfect cells such as HEK293 cells are valuable in confirming the outcome 
of experiments with BV2 cells. As expected, results in figures 5B and 5C show that 
luminescent signals from HEK293 cells were stronger than those in BV2 cells, as a 
result of a more efficient transfection of HEK293 cells. The differences in 
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luminescence in HEK293 and BV2 microglia notwithstanding, we observed 
significant (p<0.05) and concentration-dependent decrease in luminescent signals in 
both HEK293 and BV2 cells treated with urolithin A in comparison to untreated 
control cells, thus demonstrating lower levels of the LC3 reporter as a result of 
treatment with the compound. 
This is the first report showing that urolithin A increases autophagy in microglia and it 
seems to reflect earlier observations in peripheral macrophages13. These results as 
well as reports proposing a role for autophagy in inflammation in macrophages and 
microglia30, 31 urged us to study whether increasing autophagic flux in BV2 microglia 
by treatment with urolithin A might contribute to its inhibitory effects on 
neuroinflammation. Incubation of BV2 microglia with chloroquine (40 µM) followed by 
urolithin A (10 µM) prior to stimulation with LPS, resulted in a significant 
diminishment of the inhibition of LPS-induced release of pro-inflammatory mediators 
(TNFα, IL-6, and nitrite) by urolithin A (Figure 6). This observation led us to conclude 
that the ability of this compound to induce autophagy is a contributory factor in its 
ability to produce anti-inflammatory activity in BV2 microglia and in macrophages13.
Studies have linked autophagy to neuroinflammatory events in microglia. Autophagic 
processes have been shown to mediate the release of pro-inflammatory cytokines 
such as IL-1β in the microglia32. In addition, a Ginkgo biloba extract was shown to 
activate autophagy and inhibit microglia-mediated neuroinflammation in AD mouse 
brain model and primary microglia33, 34. This suggests that induction of autophagy 
by nutritional phytochemicals may be a critical strategy in preventing 
neuroinflammation in brain ageing and neurodegenerative diseases.
3.4Urolithin A prevented neurotoxicity and Aβ production in APPSwe-
transfected ReNcell VM human neural cells
The 3D human neural cell culture system is a valuable model for AD35, 36. We have 
therefore investigated the neuroprotective effects of urolithin A in these cells 
following transfection with the human APPSwe plasmid to produce the characteristic 
amyloid beta-induced neurotoxicity. Figures in S1-S3 (supplementary data) show 
differentiation of the ReNcell VM human neural cells into neurons as shown by 
immunostaining for βIII-tubulin and MAP2. Figures 7A and 7B show that transfection 
of differentiated ReNcell VM human neural cells with the APPSwe plasmid for 48 h 
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resulted in significant (p<0.001) reduction in cell viability with a corresponding 
significant (p<0.01) increase in LDH released by the cells. However, in the presence 
of urolithin A, a significant (p<0.05) and concentration-dependent neuroprotective 
activity was observed. In addition, treatment with the compound resulted in a 
significant (p<0.05) reduction in the production of the neurotoxic amyloid beta by the 
cells (Figure 7C). These results are consistent with an earlier report which showed 
that urolithin A produced neuroprotection in SH-SY5Y neuronal cells15. Similar 
results have also been reported in C. elegans following Aβ(1-42)-induced neurotoxicity 
and paralysis21. 
3.5Neuroprotection by urolithin A was reversed by inhibition of SIRT-1 and 
autophagy in APPSwe-transfected ReNcell VM human neural cells
Further experiments demonstrated that urolithin A increases the activity and protein 
levels of SIRT-1 in differentiated ReNcell VM human neural cells (Figures 8A-C), and 
that its ability to protect neural cells from amyloid-induced toxicity is dependent on 
SIRT-1 (Figures 9A and 9B). This is demonstrated by a loss of neuroprotective 
activity in the presence of EX527. SIRT-1-mediated neuroprotection by urolithin A 
reflects earlier reports showing that SIRT-1 is neuroprotective against Aβ plaque 
formation in the APPswe/PS1dE9 mouse model37. The observed SIRT-1-mediated 
neuroprotective effect of urolithin A has significant implications for its potential 
benefits in AD, as it has been reported that SIRT-1 reduced Aβ levels, oxidative 
stress, and consequently neuronal loss38. The effects of urolithin A on SIRT-1 in 
both the microglia and neural cells clearly suggest that the compound might prevent 
neurodegeneration through the inhibition of neuroinflammation and Aβ-mediated 
neurotoxicity
Studies have suggested that induction of autophagy and neuroprotection involve 
mechanisms related to activation of SIRT-139. Following our observation that 
urolithin A activates neuroprotective mechanisms such as activation of SIRT-1 in 
differentiated ReNcell VM human neural cells, we were interested in evaluating 
whether the compound also induces autophagy in these cells. Treating the cells with 
urolithin A resulted in the induction of autophagy as shown in Figures 10A and 10B. 
We further demonstrate that in the presence of chloroquine (an autophagy inhibitor), 
the neuroprotective effect of urolithin A against amyloid-induced neurotoxicity was 
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significantly reversed (Figures 11A and 11B). These results suggest a possible link 
between the activation of SIRT-1 and the induction of autophagy by urolithin A and 
its neuroprotective effects in neural cells.
4. Concluding remarks
This study to our knowledge shows for the first time that SIRT-1 activation and 
induction of autophagy are two potentially linked mechanisms involved in the anti-
inflammatory activity of urolithin A in LPS-activated BV2 microglia. These 
mechanisms also determine the neuroprotective activity of the compound in a 3D 
model of AD. It is not currently clear if autophagic induction and SIRT-1 activation by 
this compound are coupled or if they contribute independently to the neuroprotective 
effects of urolithin A in microglia and neurons.
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Figure Legends
Figure 1
Structure of urolithin A
Figure 2
Effect of urolithin A (2.5-10 µM) on NF-B-mediated pro-inflammatory mediator 
release in LPS-stimulated BV2 microglia. Treatment resulted in a reduction in the 
production of TNFα, IL-6 and nitrite in culture supernatants following incubation 
with LPS (100 ng/ml) for 24 h (A). In cell western ELISA in LPS-activated BV2 
microglia for phospho-p65 NF-B (B) and acetyl-p65 NF-B (C). Values are 
mean ± SEM for at least 3 independent experiments (**p<0.01; ***p<0.001, 
compared with LPS only; one-way ANOVA with post-hoc Tukey test).
Figure 3
Urolithin A directly activates SIRT-1 in BV2 microglia. BV2 cells were treated with 
urolithin A (2.5-10 µM) for 24 h. This was followed by ELISA to determine levels 
of SIRT-1 protein in nuclear extracts (A), luminescent SIRT-Glo assay for SIRT-1 
activity in live cells (B). Values are mean ± SEM for at least 3 independent 
experiments (ns: not significant; *p<0.05; **p<0.01; ***p<0.001, compared with 
untreated control; one-way ANOVA with post-hoc Tukey test).
Figure 4
Inhibition of neuroinflammation by urolithin A is dependent on SIRT-1. Levels of 
nitrite, TNFα and IL-6 in culture supernatants in BV2 microglia stimulated with 
LPS (100 ng/ml) were reduced in the presence of urolithin A (10 µM). However, 
in the presence of EX527 (1 µM), anti-inflammatory activity of urolithin A was 
diminished. Values are mean ± SEM for at least 3 independent experiments 
(**p<0.01; ***p<0.001 compared with untreated control. p<0.01; p<0.001, 
compared with LPS control. &&p<0.01; &&&p<0.001 compared with urolithin A 
+LPS treatment only; one-way ANOVA with post-hoc Tukey test).
Figure 5
Autophagic induction by Urolithin. Treatment of BV2 microglia resulted in 
induction of autophagy measured with a colorimetric autophagy assay kit (A). 
Transfection of HEK293 cells (B) and BV2 microglia (C) with the LC3 HiBiT 
reporter followed by treatment with urolithin A (2.5-10 µM) resulted in an increase 
in reporter activity as measured by luminescence. Values are mean ± SEM for at 
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least 3 independent experiments (ns: not significant; *p<0.05; ***p<0.001, 
compared with untreated control; one-way ANOVA with post-hoc Tukey test).
Figure 6
Autophagy induction plays a role in the anti-inflammatory activity of urolithin A in 
LPS-activated BV2 microglia. Levels of TNFα, IL-6 and nitrite in culture 
supernatants of BV2 microglia stimulated with LPS (100 ng/ml) were reduced in 
the presence of urolithin A (10 µM). However, in the presence of chloroquine 
(40 µM), anti-inflammatory activity of urolithin A was diminished. Values are 
mean ± SEM for at least 3 independent experiments (***p<0.001 compared with 
untreated control. p<0.001 compared with LPS only. &&&p<0.001 compared 
with urolithin A +LPS treatment; one-way ANOVA with post-hoc Tukey test).
Figure 7
Urolithin A produces neuroprotective effect in differentiated ReNcell VM human 
neural stem cells. Treatment of APPSwe-transfected ReNcell VM human neural 
stem cells with urolithin A (2.5-10 µM) prevented neuronal death measured with 
MTT (A) and LDH (B) assays. This was accompanied by a reduction in the 
production of amyloid beta (C). Values are mean ± SEM for at least 3 
independent experiments (*p<0.05; **p<0.01; ***p<0.001, compared with 
APPSwe-transfected cells; one-way ANOVA with post-hoc Tukey test).
Figure 8
Treatment of differentiated ReNcell VM human neural stem cells with urolithin A 
increased nuclear concentration of SIRT-1 protein (A) and increased SIRT-1 
activity in live cells (B). Immunofluorescent microscopy also shows an induction 
in nuclear accumulation of SIRT-1 in the cells (C). Values are mean ± SEM for at 
least 3 independent experiments (**p<0.01; ***p<0.001, compared with untreated 
control; one-way ANOVA with post-hoc Tukey test).
Figure 9
Loss of neuroprotection by urolithin A (10 µM) in the presence of EX527 (1 µM) in 
APPSwe-transfected ReNcell VM human neural stem cells. Neural viability was 
measured using the MTT (A) and LDH (B) assays. Values are mean ± SEM for at 
least 3 independent experiments (**p<0.01; ***P<0.001, compared with untreated 
cells. p<0.05; p<0.001, compared with APPSwe control. &&p<0.01; 
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&&&p<0.001, compared with urolithin A + APPSwe control; one-way ANOVA with 
post-hoc Tukey test).
Figure 10
Treatment of differentiated ReNcell VM human neural stem cells resulted in 
induction of autophagy measured with a colorimetric autophagy assay kit (A). 
Transfection of differentiated ReNcell VM human neural stem cells with the LC3 
HiBiT reporter followed by treatment with urolithin A (2.5-10 µM) resulted in an 
increase in reporter activity as measured by luminescence (B). Values are mean 
± SEM for at least 3 independent experiments (ns: not significant; *p<0.05; 
**p<0.01; ***p<0.001, compared with untreated control; one-way ANOVA with 
post-hoc Tukey test).
Figure 11
Reversal of neuroprotection by urolithin A (10 µM) in APPSwe-transfected 
ReNcell VM human neural stem cells in the presence of chloroquine (40 µM) was 
measured with MTT (A) and LDH (B) assays. Values are mean ± SEM for at least 
3 independent experiments (***p<0.001; compared with untreated cells. 
p<0.001, compared with APPSwe control. &&p<0.01; &&&p<0.001, compared 
with urolithin A + APPSwe control; one-way ANOVA with post-hoc Tukey test).
Supplementary Figure 1 (S1)
Immunofluorescence detection of nestin in undifferentiated ReNcell VM human 
neural stem cells.
Supplementary Figure 2 (S2)
Immunofluorescence detection of βIII tubulin in differentiated ReNcell VM human 
neural stem cells.
Supplementary Figure 3 (S3)
Immunofluorescence detection of MAP2 in differentiated ReNcell VM human 
neural stem cells.
Supplementary Figure 4 (S4)
Treatment of BV2 microglia with urolithin A (2.5-10 µM), followed by stimulation 
with LPS (100 ng/ml) for 24 h did not affect cell viability as determined by MTT 
viability assay.
Supplementary Figure 5 (S5)
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Immunofluorescent analyses showing that pre-treatment with urolithin A (2.5-
10 µM) resulted in inhibition of nuclear accumulation of NF-B p65 sub-unit (A) 
and acetylation (B) in BV2 microglia stimulated with LPS (100 ng/ml) for 60 min.
Supplementary Figure 6 (S6)
Immunoflurescent detection of SIRT-1 protein following treatment of BV2 
microglia with urolithin A (2.5-10 M).
Supplementary Figure 7 (S7)
Immunofluorescence showing SIRT-1-dependent inhibition of nuclear localisation 
of NF-B in LPS-stimulated BV2 microglia by urolithin A.
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